0.32%
14.90%
22.68%
39.19%
67.76%
140.19%
137.36%
AI Spotlight on BSX
Company Description
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular.The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.
It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems.In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies.Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer.
The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Market Data
| Last Price | 103.04 |
| Change Percentage | 0.32% |
| Open | 103.6 |
| Previous Close | 102.71 |
| Market Cap ( Millions) | 151863 |
| Volume | 5260438 |
| Year High | 104.24 |
| Year Low | 63.39 |
| M A 50 | 92.58 |
| M A 200 | 82.13 |
Financial Ratios
| FCF Yield | 1.29% |
| Dividend Yield | 0.00% |
| ROE | 8.91% |
| Debt / Equity | 54.37% |
| Net Debt / EBIDTA | 234.56% |
| Price To Book | 7.33 |
| Price Earnings Ratio | 84.82 |
| Price To FCF | 77.28 |
| Price To sales | 9.55 |
| EV / EBITDA | 43.03 |
News
- Jan -30 - Will Cheaper AI Models Like DeepSeek Become a Boon? 3 Stocks to Watch
- Jan -29 - BSX Pre-Q4 Earnings: To Buy or Not to Buy Boston Scientific Stock Now?
- Jan -28 - Boston Scientific (BSX) Increases Despite Market Slip: Here's What You Need to Know
- Jan -20 - BSX Stock Rises on Positive Data Announcement at the AF Symposium
- Jan -17 - Boston Scientific (BSX) Increases Yet Falls Behind Market: What Investors Need to Know
- Jan -16 - Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation
- Jan -15 - M&A Synergies Drive BSX: Is it Worth Buying the Stock Now?
- Jan -15 - Boston Scientific Jumps Ahead of Earnings
- Jan -14 - Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
- Jan -10 - Stocks on the move: Delta, Constellation Energy, Wynn, Sweetgreen and Boston Scientific
- Jan -09 - BSX Stock Rises Following Bolt Medical Acquisition Deal Announcement
- Jan -08 - Boston Scientific Expands Cardiovascular Treatment Portfolio With $440 Million+ Bolt Medical Deal
- Jan -08 - Boston Scientific Announces Agreement to Acquire Bolt Medical, Inc.
- Jan -07 - Endoscopy Sales Growth to Support BSX Stock Amid Fierce Competition
- Jan -07 - Boston Scientific (BSX) Outperforms Broader Market: What You Need to Know
- Jan -06 - Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
- Jan -03 - 5 Non-Tech Outperformers of 2024 Set to Fly Higher in the Near Term
- Jan -02 - Boston Scientific Announces Participation in the J.P. Morgan Healthcare Conference and Conference Call Discussing Fourth Quarter 2024 Results
- Jan -02 - Is Boston Scientific Stock a Smart Pick for Your Portfolio Right Now?
- Jan -01 - Why Boston Scientific (BSX) is Poised to Beat Earnings Estimates Again
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Cardiovascular
Expected Growth : 8 %
What the company do ?
Boston Scientific's Cardiovascular segment offers a range of medical devices and solutions for cardiovascular diseases, including coronary stents, cardiac rhythm management, and structural heart therapies.
Why we expect these perspectives ?
Boston Scientific's Cardiovascular segment growth is driven by increasing demand for minimally invasive procedures, adoption of advanced technologies such as fractional flow reserve (FFR) and intravascular ultrasound (IVUS), and expansion into emerging markets. Additionally, the company's strategic acquisitions and investments in research and development have enhanced its product portfolio, contributing to the 8% growth rate.
Segment n°2 -> MedSurg
Expected Growth : 10 %
What the company do ?
MedSurg is a medical technology segment from Boston Scientific Corporation that develops and commercializes medical devices for various medical specialties.
Why we expect these perspectives ?
Boston Scientific's MedSurg segment growth is driven by increasing demand for minimally invasive procedures, advancements in robotics and navigation, and expansion into emerging markets. Additionally, the company's strategic acquisitions, such as the purchase of BTG, have enhanced its portfolio and fueled growth.
Segment n°3 -> Reconciling Items
Expected Growth : 9 %
What the company do ?
Reconciling Items from Boston Scientific Corporation refers to the process of resolving discrepancies between the company's financial records and actual transactions, ensuring accuracy and transparency in financial reporting.
Why we expect these perspectives ?
Boston Scientific Corporation's 9% growth is driven by increasing demand for minimally invasive medical devices, strategic acquisitions, and geographic expansion into emerging markets. Additionally, investments in research and development have led to innovative product launches, further fueling growth. The company's focus on cost savings initiatives and operational efficiencies has also contributed to its strong performance.
Boston Scientific Corporation Products
| Product Range | What is it ? |
|---|---|
| Cardiac Rhythm Management (CRM) Devices | Devices that help regulate the heartbeat, including pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices. |
| Electrophysiology (EP) Products | Devices and catheters used to diagnose and treat abnormal heart rhythms, including ablation catheters and diagnostic catheters. |
| Endoscopy Products | Devices and instruments used to visualize and treat conditions in the digestive tract, including endoscopes, balloons, and snares. |
| Interventional Cardiology Products | Devices and systems used to treat coronary artery disease, including angioplasty balloons, stents, and guidewires. |
| Neuromodulation Products | Devices and systems used to treat chronic pain, movement disorders, and other neurological conditions, including spinal cord stimulators and deep brain stimulators. |
| Peripheral Interventions Products | Devices and systems used to treat peripheral artery disease, including angioplasty balloons, stents, and atherectomy systems. |
| Urology and Pelvic Health Products | Devices and systems used to treat urological and pelvic health conditions, including urinary incontinence, pelvic organ prolapse, and kidney stones. |
Boston Scientific Corporation's Porter Forces
Threat Of Substitutes
Boston Scientific Corporation faces moderate threat from substitutes, as patients may opt for alternative treatments or products from other companies, but the company's strong brand reputation and product offerings mitigate this threat to some extent.
Bargaining Power Of Customers
Boston Scientific Corporation has a diverse customer base, which reduces the bargaining power of individual customers, and the company's strong relationships with hospitals and healthcare providers further limit customer bargaining power.
Bargaining Power Of Suppliers
Boston Scientific Corporation relies on a network of suppliers for raw materials and components, and while the company has some bargaining power due to its size, suppliers may still exert some pressure on prices and delivery terms.
Threat Of New Entrants
The medical device industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise, making it difficult for new entrants to challenge Boston Scientific Corporation's market position.
Intensity Of Rivalry
The medical device industry is highly competitive, with several established players, including Medtronic, Abbott, and Johnson & Johnson, competing fiercely for market share, which increases the intensity of rivalry for Boston Scientific Corporation.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 32.99% |
| Debt Cost | 3.95% |
| Equity Weight | 67.01% |
| Equity Cost | 7.79% |
| WACC | 6.52% |
| Leverage | 49.23% |
Boston Scientific Corporation : Quality Control
Boston Scientific Corporation passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| DXCM | DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems … |
| ABBV | AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat … |
| ABT | Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. … |
| SYK | Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use … |
| MCK | McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
AbbVie
A-Score
1-Year Total Return ->
🥈
McKesson
A-Score
1-Year Total Return ->
🥉
Abbott
A-Score
1-Year Total Return ->
4
Stryker
A-Score
1-Year Total Return ->
5
Boston Scientific
A-Score
1-Year Total Return ->
6
